Stockscreener 앱 받기
24.19
1.72%
0.41
시간 외 거래:
24.19
전일 마감가:
$23.78
열려 있는:
$23.47
하루 거래량:
1.91M
Relative Volume:
1.13
시가총액:
$4.22B
수익:
-
순이익/손실:
$-382.71M
주가수익비율:
-9.2328
EPS:
-2.62
순현금흐름:
$-325.64M
1주 성능:
+10.05%
1개월 성능:
+43.14%
6개월 성능:
+53.10%
1년 성능:
-17.78%
1일 변동 폭
$23.31
$24.54
1주일 범위
$21.34
$26.17
52주 변동 폭
$12.72
$32.10
Immunovant Inc Stock (IMVT) Company Profile
명칭
Immunovant Inc
전화
917-580-3099
주소
320 WEST 37TH STREET, NEW YORK, NY
IMVT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
24.19 | 4.15B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-14 | 개시 | Truist | Hold |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-03-03 | 개시 | Jefferies | Hold |
| 2025-01-03 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-09 | 재확인 | Oppenheimer | Outperform |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2024-03-13 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | JP Morgan | Overweight |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-13 | 업그레이드 | UBS | Neutral → Buy |
| 2023-09-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 개시 | BofA Securities | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-31 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2023-02-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2021-08-03 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-01 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-12 | 개시 | Guggenheim | Buy |
| 2020-10-08 | 개시 | Stifel | Buy |
| 2020-10-02 | 개시 | Credit Suisse | Outperform |
| 2020-08-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | SVB Leerink | Outperform |
모두보기
Immunovant Inc 주식(IMVT)의 최신 뉴스
Immunovant (IMVT) Projected to Post Quarterly Earnings on Monday - MarketBeat
Why Immunovant Inc. stock is popular among millennialsJuly 2025 Drop Watch & Intraday High Probability Alerts - newser.com
Will Immunovant Inc. stock outperform value stocksPortfolio Value Summary & AI Forecasted Entry and Exit Points - newser.com
Is Immunovant Inc. meeting your algorithmic filter criteriaJuly 2025 Pullbacks & High Yield Stock Recommendations - newser.com
Analyzing net buyer seller activity in Immunovant Inc.Options Play & Weekly Return Optimization Plans - newser.com
Sentiment analysis tools applied to Immunovant Inc.Portfolio Risk Report & Free Technical Pattern Based Buy Signals - newser.com
Is Immunovant Inc. stock affected by interest rate hikesQuarterly Portfolio Summary & Growth Oriented Trading Recommendations - newser.com
Can swing trading help recover from Immunovant Inc. lossesJuly 2025 Price Swings & Verified Stock Trade Ideas - newser.com
Will Immunovant Inc. stock go up soonJuly 2025 Weekly Recap & Stock Portfolio Risk Control - newser.com
How analysts rate Immunovant Inc. stock todayJuly 2025 Fed Impact & Consistent Profit Alerts - newser.com
Why analysts upgrade Immunovant Inc. stockWeekly Trade Review & Safe Entry Momentum Stock Tips - newser.com
Evaluating Immunovant (IMVT): Does Recent Momentum Signal a Premium Valuation? - Yahoo Finance
How to use Fibonacci retracement on Immunovant Inc.Quarterly Profit Review & Consistent Return Strategy Ideas - newser.com
Immunovant (IMVT) Soars 14.6% Ahead of Q3 Results - MSN
Key resistance and support levels for Immunovant Inc.2025 EndofYear Setup & Stock Portfolio Risk Control - newser.com
Is Immunovant Inc. stock oversold or undervaluedWeekly Market Report & Precise Entry and Exit Recommendations - newser.com
Immunovant (NASDAQ:IMVT) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Immunovant: Takeover Buzz, IMVT-1402 Promise, And Why I'm Staying Neutral (NASDAQ:IMVT) - Seeking Alpha
Published on: 2025-10-31 03:05:59 - newser.com
How institutional ownership impacts Immunovant Inc. stockWeekly Profit Report & Safe Capital Growth Stock Tips - newser.com
Immunovant gains amid takeover speculation (IMVT:NASDAQ) - Seeking Alpha
IMMUNOVANT Earnings Preview: Recent $IMVT Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Immunovant Inc (IMVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immunovant Inc 주식 (IMVT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Stout Jay S | Chief Technology Officer |
Oct 22 '25 |
Sale |
19.03 |
2,520 |
47,956 |
200,814 |
| Geffner Michael | Chief Medical Officer |
Oct 08 '25 |
Sale |
16.30 |
1,272 |
20,734 |
220,553 |
| Stout Jay S | Chief Technology Officer |
Oct 08 '25 |
Sale |
16.30 |
1,585 |
25,836 |
203,334 |
| Stout Jay S | Chief Technology Officer |
Jul 23 '25 |
Sale |
18.15 |
2,805 |
50,911 |
204,919 |
| Geffner Michael | Chief Medical Officer |
Jul 23 '25 |
Sale |
18.15 |
2,385 |
43,288 |
221,825 |
| Geffner Michael | Chief Medical Officer |
Jul 09 '25 |
Sale |
17.24 |
1,160 |
19,998 |
224,210 |
| Stout Jay S | Chief Technology Officer |
Jul 09 '25 |
Sale |
17.24 |
1,519 |
26,188 |
207,724 |
1.29%
0.56%
자본화:
|
볼륨(24시간):